Tuesday, 28 June 2022


Singapore develops new glaucoma implant that reduces eye pressure

12 November 2021 | News

The implant has undergone rigorous safety and biocompatibility studies in the laboratory and in animal studies before being implanted in patients

image credit- NUS Singapore

image credit- NUS Singapore

A new glaucoma implant developed by a National University Health System team in Singapore reduces patients’ eye pressure (also known as intraocular pressure, IOP) for a longer period of time and enables less reliance on eye drops.

The Paul Glaucoma Implant (PGI) is a glaucoma drainage device which regulates IOP and prevents further progression of the disease that leads to blindness.

With a higher efficacy and safety profile in reducing IOP, this medical technology innovation advances the treatment of glaucoma. In patients with medically uncontrolled glaucoma, the PGI offers a viable option in the management of refractory glaucoma, a severe form of glaucoma that has a high risk of failure from conventional trabeculectomy surgery.

The implant is licensed to a startup company Advanced Ophthalmic Innovations Pte Ltd (AOI) and has been used for glaucoma treatments in Singapore, Europe, South Africa, Middle-east, and Asia-Pacific.

"An important aim that we have achieved with the Paul Glaucoma Implant is to design a shunt that is less invasive inside the eye, with its much smaller tube than conventional implants, without compromising efficacy across the spectrum of recalcitrant glaucomas,” added Professor Keith Barton, a glaucoma specialist with Moorfields Eye Hospital in the United Kingdom and a visiting Professor with NUS Medicine. He was also involved in the design phase of the PGI.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account